News & Events about Abcellera Biologics Inc.
AbCellera Biologics Inc. (NASDAQ:ABCL Get Rating) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 15,350,000 shares, a decline of 7.0% from the November 30th total of 16,510,000 shares. ...
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCelleras antibody...
Business Wire
2 months ago
AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. AbCelleras poster...
Business Wire
2 months ago
AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development. The partnership, which...
Business Wire
7 months ago
AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCelleras collaboration with Lilly, for approximately...